IN Brief:
- The Council and European Parliament have reached a provisional agreement on the Critical Medicines Act.
- The rules aim to strengthen supply chains for antibiotics, insulin, painkillers, and other critical medicines.
- Procurement, contingency stocks, collaborative purchasing, and EU-based API production are central to the package.
The Council of the European Union and the European Parliament have reached a provisional agreement on the Critical Medicines Act, moving the bloc closer to new supply resilience rules for essential medicines and active pharmaceutical ingredients.
The proposed regulation is designed to reduce shortages of critical medicines including antibiotics, insulin, painkillers, vaccines, and treatments for chronic and acute diseases. It also covers medicines of common interest where access varies across member states or where market conditions weaken security of supply.
Before becoming law, the agreement still requires formal endorsement by the Council and Parliament, followed by legal-linguistic revision and adoption. Once in force, it will add a stronger industrial and procurement layer to European medicines policy, sitting alongside wider reforms to the EU pharmaceutical framework.
Public procurement sits at the centre of the package. Contracting authorities will be expected to give supply security greater weight when buying critical medicines, reducing reliance on lowest-price purchasing where the product is strategically important or exposed to disruption. That approach could reshape tender design, supplier qualification, stock requirements, and sourcing decisions across healthcare systems.
The act also supports EU-based manufacturing of critical medicines and active pharmaceutical ingredients. Many essential medicines rely on concentrated production networks outside Europe, creating exposure to export controls, transport disruption, sudden demand spikes, quality failures, and supplier shutdowns. Bringing more production closer to European demand is being treated as part of healthcare resilience rather than a narrow industrial-policy preference.
Active pharmaceutical ingredients are a particular concern because supply fragility often begins long before a finished medicine reaches a hospital pharmacy, wholesaler, or cold-chain warehouse. APIs sit upstream of packaging, batch release, distribution, and clinical use. When API supply tightens, the visible shortage appears later, usually at the point where healthcare systems have fewer alternatives.
The provisional deal also changes collaborative procurement. The threshold for member states to ask the Commission to procure on their behalf has been reduced from nine to five, giving smaller groups of countries a faster route to pool demand and increase buying leverage. In shortage-prone categories, that could reduce fragmentation and help avoid member states competing against one another for constrained supply.
Contingency stocks form another strand of the proposal. The agreement preserves safeguards designed to prevent national stockpiling measures from undermining other member states or disrupting the EU internal market. It also introduces measures for sharing information about contingency stock requirements and clarifies the use of a voluntary solidarity mechanism so member states can exchange stock data and reallocate products when needed.
Pharmaceutical logistics is already moving towards more resilient and controlled networks. Maersk’s Hyderabad pharma reefer rail corridor added a scheduled inland cold-chain route for Indian pharmaceutical exports, showing how healthcare supply chains are being redesigned around predictable movement, temperature integrity, and gateway reliability.
The EU act sits higher up the policy chain, but the operational consequences are clear. Regional production, stronger procurement requirements, and greater stock transparency will affect where medicines and ingredients move, how suppliers qualify for contracts, and what documentation is needed to prove resilience. Warehousing, freight forwarding, temperature-controlled transport, customs processes, quality assurance, and inventory visibility all sit inside that shift.
The agreement also extends into orphan medicinal products in certain areas, including strategic projects and collaborative procurement. These medicines treat rare, serious, or life-threatening conditions, where disruption can leave patients and healthcare systems with few alternatives. Including them reinforces the move towards assessing supply resilience by treatment risk as well as volume.
Healthcare supply chains now sit at the intersection of industrial capacity and clinical need. A shortage may begin with raw materials, APIs, packaging, batch release, manufacturing constraints, regulatory delays, or transport disruption, but the failure is measured in care delivery. The Critical Medicines Act attempts to close that gap by making supply security a formal part of procurement, manufacturing, and stock policy.
Converting regulation into capacity will still be difficult. Pharmaceutical production requires specialist plants, qualified suppliers, regulatory approvals, skilled labour, validated logistics networks, and reliable demand. Resilience criteria may improve the investment case for suppliers that build EU capacity, but price pressure, reimbursement systems, and public procurement budgets will continue to shape what is commercially viable.
For manufacturers, wholesalers, logistics providers, and procurement teams, critical medicine supply is being redefined around continuity, geographic risk, stock transparency, and response capability. Cheapest compliant supply will no longer be the only benchmark in categories where shortage risk can turn a purchasing decision into a healthcare failure.
